We have contained the traditional granular demineralized bone
matrix (DBM) in three distinct delivery systems and we have
developed a test that improves the consistency of the clinical
Our breakthrough technology evolves around the innovative
carriers we use for our DynaGraft product line, which consists
of DynaGraft Gel, DynaGraft Putty and DynaGraft Matrix. The
conventional DBM granules are contained by Gel (47% DBM/volume)
and Putty (64% DBM/volume) carriers, consisting of a reverse
phase copolymer, which has the unique characteristic of being
malleable at room temperature, but firms when exposed to the
higher temperature of the graft site.
The Matrix (60% DBM/weight) carrier is a glycoprotein sponge
(Type I collagen) which provides blood clot formation and can
easily be manipulated in situ.
All three DynaGraft presentations contain human demineralized
bone matrix (DBM) which we obtain from tissue banks that are
members of the American Association of Tissue Banks (AATB). In
order to reduce the variability of the clinical results, we have
developed a test that indicates the level of osteoinductive
potential (the potential to grow bone) of the bone tissue that
we receive from the tissue banks. This in vitro test assays for
alkaline phosphatase, a derivative of osteoblastic activity.
This process guarantees consistent bone regenerative activity
each time DynaGraft is used (in other words predictability).
bone mill used to grind bone harvested from the patient site,
which will improve the osteoinduction and therefore the
formation of new bone. The osteodisc is a class 1 medical
device, is CE marked and is currently sold in Canada and in the
US in the orocraniofacial and orthopedic markets
Neomem membrane is a Type 1 bovine collagen matrix and is
indicated for use in guided tissue regeneration (GTR) and guided
bone regeneration (GBR) procedures, as well as use associated
with dental implants, bone defects and ridge augmentation to aid
in wound healing post surgery.
Inion GTR membrane
The Inion GTR Membrane is the first-ever membrane that is soft when applied but becomes rigid, once fixed in position. The key advantage of this is the ability to maintain space between soft tissue and bone, thus allowing for a large bone volume to be regenerated. Pre-clinical studies suggest a bioactive agent in the membrane may facilitate faster bone regeneration. The agent elutes out following implantation.
Accell Connexus® is a robust putty that provides exceptional handling and graft containment characteristics while maximizing osteoinductivity. By utilizing a unique reverse phase medium, Connexus thickens at body temperature and resists irrigation so it stays at the surgical site.
Connexus also takes advantage of the proprietary Accell® processing technique to deliver a demineralized bone matrix (DBM) putty with high osteoinductivity. DBM is the source for an array of growth factors, including natural human bone morphogenetic proteins (nhBMPs), the osteoinductive triggers found in bone. The Accell process releases additional nhBMPs resulting in a higher concentration of synergistic growth factors working in concert to produce new bone.
DynaBlast is a composite graft product that combines osteoinductive and osteoconductive elements in a proprietary, reverse phase medium. This powerful 2-in-1 solution combines:
Demineralized bone, which stimulates new bone growth,
and Cancellous bone chips, which provide a natural structural scaffold to encourage the attachment of osteogenic precursor cells
DynaBlast can be used either alone or as a bone graft extender indicated for augmentation or reconstructive treatment of the alveolar ridge.
Using the mineral building blocks naturally found in human bone, Eclipse goes a step beyond the realm of everyday hydroxyapatite (HA) and tricalcium phosphate (TCP) with its unique combination of micro and macroporosity technology.
The Eclipse key to balanced bone regeneration is its unique ratio between micro and macro porosity and its unique ratio between HA and ß-TCP.
80% ß-TCP calcium and phosphate ion release
20% HA scaffold effect for osteoblastic activity
70% overall porosity
- 2/3 macroporosity
- 1/3 microporosity